Sign In
Buy HRTX
$0.447
-0.0032 (-0.711%)
At Close: Jun 03, 2026
Heron Therapeutics (HRTX) Investor Presentation - Slideshow
09:50am, Tuesday, 08'th Sep 2020
The following slide deck was published by Heron Therapeutics, Inc. in conjunction with this event..
Landec Corp (LNDC) Q4 2020 Earnings Call Transcript
05:00am, Wednesday, 12'th Aug 2020
LNDC earnings call for the period ending May 31, 2020.
The Global Chemotherapy-induced Nausea and Vomiting Drugs Market will grow by $ 525 mn during 2020-2024
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
10:30pm, Sunday, 09'th Aug 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
10:35pm, Wednesday, 05'th Aug 2020
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Did Hedge Funds Make The Right Call On Heron Therapeutics Inc (HRTX) ?
03:26pm, Tuesday, 04'th Aug 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04:31pm, Monday, 27'th Jul 2020
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics' (NASDAQ:HRTX) Stock Price Has Reduced48% In The Past Five Years
02:29pm, Friday, 24'th Jul 2020
While not a mind-blowing move, it is good to see that the Heron Therapeutics, Inc. (NASDAQ:HRTX) share price has...
Heron's Cinvanti Progress, And Other News: The Good, Bad And Ugly Of Biopharma
10:46pm, Thursday, 16'th Jul 2020
Heron Therapeutics advances Phase 2 Study of CINVANTI. BridgeBio Pharma starts dosing in Phase 2 clinical trial.
Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19
12:30pm, Thursday, 16'th Jul 2020
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan
Parametric Portfolio Associates LLC Decreases Stock Position in Heron Therapeutics Inc (NASDAQ:HRTX)
04:30am, Sunday, 05'th Jul 2020
Parametric Portfolio Associates LLC cut its holdings in Heron Therapeutics Inc (NASDAQ:HRTX) by 40.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 68,411 shares of t
Heron Therapeutics Inc (NASDAQ:HRTX) Expected to Announce Earnings of -$0.60 Per Share
06:06am, Friday, 03'rd Jul 2020
Analysts expect Heron Therapeutics Inc (NASDAQ:HRTX) to report earnings of ($0.60) per share for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Heron Therapeutics’
Heron Therapeutics (HRTX) in Focus: Stock Moves 9% Higher
02:38am, Friday, 03'rd Jul 2020
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst
06:26pm, Wednesday, 01'st Jul 2020
It was a difficult start to the week for Heron Therapeutics (HRTX). Monday saw shares plunge after the small-cap biotech received another CRL (complete response letter) for its experimental post-opera
2 Biotech Stocks That Could Soar in 2020 | The Motley Fool
11:12am, Wednesday, 01'st Jul 2020
These companies offer promising pipelines that could deliver in the long term.
